MERETEK UBT KIT (W/ PRANACTIN)
LOE ApproachingNDAORALFOR SOLUTION
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MERETEK UBT KIT (W/ PRANACTIN) is an oral solution kit developed by Otsuka, approved in 1996 for diagnostic purposes. The product is formulated as an oral solution and represents a diagnostic/therapeutic combination approach. Specific indications and mechanism of action are not publicly detailed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting downsizing commercial operations or transition planning underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring on this product; career growth is limited. Professionals on this team should anticipate product transitions, consolidation, or portfolio rationalization.
Brand ManagerMarketing Manager
Worked on MERETEK UBT KIT (W/ PRANACTIN) at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.